Alterity Therapeutics Announces Regulator... - Cure Parkinson's

Cure Parkinson's

26,491 members27,905 posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

0 Replies

asiaone.com/business/alteri...

Alterity's lead candidate, ATH434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain. In this way, it has excellent potential to treat Parkinson's disease as well as various forms of atypical Parkinsonism such as Multiple System Atrophy (MSA). ATH434 has successfully completed a Phase 1 clinical trial demonstrating the agent is well tolerated, orally bioavailable, and achieved brain levels comparable to efficacious levels in animal models of MSA, with the objective of restoring function in patients with MSA and other Parkinsonian disorders.

ATH434 has been granted Orphan designation for the treatment of MSA by the U.S. FDA and the European Commission.

Read more about...

Not what you're looking for?

You may also like...

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s...

ANNOVIS BIO ANNOUNCES POSITIVE FDA FEEDBACK FOR BUNTANETAP PHASE 3 CLINICAL DEVELOPMENT IN PARKINSON'S DISEASE (ANVS401)

https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?releaseID=111474&d=20

BioVie announces treatment of 1st patient in Phase 2 clinical trial of NE3107,ERK inhibitor that selectively inhibits neuroinflammation

BioVie announces treatment of 1st patient in Phase 2 clinical trial of NE3107 (an ERK inhibitor...

Phase 2 Mesenchymal Stem Cell Trial in USA

"A newly opened Phase 2 clinical trial is evaluating adult stem cells as a potentially...
jimcaster profile image

Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial

' Once-a-day treatment with oral ANVS401 was found to significantly improve motor skills among...